Ravi Hira, MD
Interventional Cardiology · Seattle, WANPI 1447414164
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $39,025 of the $63,504 with a category attached, or 61.5%. Abbott accounts for 69.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2020 at $23,736 and has fallen 97.9% since, to $501 in 2025. Among interventional cardiology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $542.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$44K
- Asahi Intecc USA, Inc.$6K
- Abiomed$6K
- Medtronic$3K
- Opsens Inc.$3K
- Boston Scientific$1K
- plus $1K from 11 others
Across 54 payments — averaging $3702.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$96K
- Roche Diagnostics Operations, Inc.$69K
- Janssen Research & Development, LLC$27K
- Medtronic$8K
What the payments were for
- Consulting fees$39,02561%
- Speaking & faculty fees$12,95020%
- Travel & lodging$7,20911%
- Food & beverage$4,3017%
- Entertainment$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 63 | $43,826 |
| Asahi Intecc USA, Inc. | 4 | $5,841 |
| Abiomed | 9 | $5,699 |
| Medtronic(2 entities) | 9 | $3,086 |
| Opsens Inc. | 4 | $2,524 |
| Boston Scientific | 8 | $1,342 |
| Cardiovascular Systems Inc. | 3 | $393 |
| Celonova Biosciences, Inc. | 1 | $213 |
| Novartis | 5 | $127 |
| Biotronik Inc. | 1 | $112 |
| Janssen Scientific Affairs, LLC | 1 | $106 |
| Shockwave Medical, Inc | 1 | $86 |
| Penumbra, Inc. | 3 | $67 |
| Amgen | 2 | $39 |
| Cardiva Medical, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$30,338
- HI-TORQUE WIGGLE$6,500
- ASAHI PTCA Guide Wire$5,787
- Impella$5,396
- Dragonfly OCT$4,147
- Resolute$2,700
- SavvyWire$2,475
- DRAGONFLY OPSTAR$902
- EMERGE$800
- HI-TORQUE BALANCE$747
- SYMPLICITY G3$267
- Coronary Orbital Atherectomy System$256
- Xience Sierra Coronary Stent$128
- Diamondback Coronary$123
- STINGRAY$119
- OPTICROSS$112
- XARELTO$106
- SYNERGY$100
How this compares
$63,504 in reported general payments places this provider in the 90th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 177 | $212,370 |
| XareltoRivaroxaban | 49 | $48,231 |
| EntrestoSacubitril/Valsartan | 22 | $31,888 |
| FarxigaDapagliflozin Propanediol | 24 | $31,025 |
| BrilintaTicagrelor | 20 | $16,348 |
| JardianceEmpagliflozin | 11 | $15,785 |
| Metoprolol Succinate | 348 | $4,926 |
| Rosuvastatin Calcium | 131 | $3,766 |
| Atorvastatin Calcium | 306 | $2,755 |
| ClopidogrelClopidogrel Bisulfate | 133 | $1,824 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 109 | $1,655 |
| Losartan Potassium | 121 | $1,264 |
| Ranolazine ErRanolazine | 21 | $1,153 |
| Amlodipine Besylate | 153 | $989 |
| Lisinopril | 117 | $864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $13 | $48,23149 claims |
| NovartisEntresto | $127 | $31,88822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 125 interventional cardiology providers in Washington.
Other interventional cardiology in Seattle
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Danny DvirSeattle$374K
- James McCabeSeattle$289K
- Christopher BrownSeattle$266K
- Lorenzo AzzaliniSeattle$233K
- Sidakpal PanaichSeattle$214K
- Christine ChungSeattle$210K
- Sameer GafoorSeattle$80K
- Ming ZhangSeattle$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.